Compounds and methods for treating diabetic vascular diseases

• US 20060058268A1
• Filed: 06/30/2005
• Published: 03/16/2006
• Est. Priority Date: 07/01/2004
• Status: Abandoned Application

• Current Assignee: Salutria Pharmaceuticals, LLC
• Original Assignee: Salutria Pharmaceuticals, LLC
• Inventors: Kunsch, Charles, Sundell, Cynthia L.
• Application Number:
  US11/171,847
• Publication Number:
  US 20060058268A1
• Time in Patent Office: Days
• US Class Current: 514/114
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/225 Polycarboxylic acids
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Compositions and methods of use of compounds of the formula
and pharmaceutically acceptable salts thereof for the treatment of diabetic vascular diseases such as diabetic neuropathy, nephropathy, and retinopathy are described, wherein the substituents of the compound are further defined within the application.

Claims

1. A method for treating diabetic vascular disease, diabetic neuropathy, nephropathy, or retinopathy in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula I

2. A method for treating diabetic vascular disease in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula I

3. A method for treating diabetic neuropathy, nephropathy, or retinopathy in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula I

4. A method for treating diabetic vascular disease in a mammal, the method comprising administering to the mammal in need thereof an effective amount of a compound of Formula II

5. The method of claim 4, wherein Y is a bond or C

6. The method of claim 4, wherein

Y is a bond or

Z is selected from the group consisting of C_1-10 alkyl, C_2-10 alkenyl, C_2-10 alkynyl, hydroxyl C_1-10 alkyl, and aryl, wherein all may optionally be substituted by one or more R₅;

R₅ is independently selected from the group consisting of hydroxyl, COOH, COOR₇, OC(O)R₇; and

R₇ is independently selected from the group consisting of C_1-10 alkyl, C_2-10 alkenyl, C_2-10 alkynyl, and C_1-10 alkoxy.

7. The method of claim 4, wherein the compound or its pharmaceutically acceptable salt are selected from the group consisting of

8. The method of claim 7, wherein the compound or its pharmaceutically acceptable salt is

9. The method of claim 4, wherein the compound or its pharmaceutically acceptable salt are administered through a conjunctival administration, nasal administration, a buccal administration, an epidermal administration, or a parenteral administration.

10. The method of claim 4, wherein the compound or its pharmaceutically acceptable salt are administered orally.

11. The method of treating diabetic vascular disease according to claim 4, wherein the compound or its pharmaceutically acceptable salt are administered through a conjunctival administration.

12. The method of treating diabetic vascular disease according to claim 11, wherein the compound or its pharmaceutically acceptable salt is administered through the conjunctival administration in a form of an ophthalmic solution, an ophthalmic suspension, an ophthalmic gel, an ophthalmic ointment, or an ophthalmic strip or insert.

13. The method of claim 4, wherein the administration is in an amount of from about 0.01 mg/kg/day to about 1000 mg/kg/day.

14. The method of claim 4, wherein the therapeutically effective amount is in the form of a pharmaceutical formulation comprising the compound and a suitable carrier or excipient thereof.

15. A method for the treatment of a human afflicted with a diabetic vascular disease, the method comprising administering to the human in need of such a treatment a therapeutically effective amount of a composition comprising a compound represented by the formula: